Cambridge Network

Amphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

The first-in-human ‘BRAMLIE’ (BR (D9) AML Interventional Evaluation) trial will assess the safety, pharmacokinetics and ...
Cambridge Network

42 Technology demonstrates neuromorphic AI for always-on condition monitoring

42 Technology (42T), the Cambridge-based product development and manufacturing innovation consultancy, has developed an ...
Cambridge Network

Only 13% of telecom operators say their network data is largely accurate, putting service activations and M&A at risk

Industry survey of 500 senior telecom decision-makers finds operators are flying blind on physical network data, and it’s ...
Cambridge Network

Guardtech gearing up for an action-packed 2026 exhibition finale

GUARDTECH are gearing up for a busy end to 2026, with four major industry events set to provide the perfect platform for ...